1. Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM), 2013. Public assessment report scientific discussion: ezetimib sandoz 10 mg tabletten ezetimibe (AT/H/0441/001/DC), https://mri.cts-mrp.eu/Human/Downloads/AT_H_0441_001_PAR.pdf, accessed 11 Oct 2021.
2. Significance of metabolites in bioequivalence: losartan potassium as a case study;Charoo;J. Pharm. Sci.,2014
3. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia;Davidson;J. Am. Coll. Cardiol.,2002
4. EMA, 2010. Guideline on the investigation of bioequivalence (CPMP/EWP/QWP/1401/98 Rev. 1/Corr **), https://www.ema.europa.eu/en/investigation-bioequivalence#current-effective-version-section, accessed 11 Oct 2021.
5. EMA, 2019a. Ezetimibe tablet 10 mg product-specific bioequivalence guidance, https://www.ema.europa.eu/en/documents/scientific-guideline/ezetimibe-tablet-10-mg-product-specific-bioequivalence-guidance_en.pdf accessed 11 Oct 2021.